<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496209</url>
  </required_header>
  <id_info>
    <org_study_id>RECONSTRUCT</org_study_id>
    <nct_id>NCT01496209</nct_id>
  </id_info>
  <brief_title>REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts</brief_title>
  <acronym>RECONSTRUCT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blinded and placebo-controlled, dose escalation, single-center safety and
      preliminary efficacy study of cardiospheres delivered via NOGA MYOSTAR injection catheter in
      subjects with chronic ischemic cardiomyopathy. The objective is to achieve and document
      myocardial regeneration in patients with chronic scar.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Chronic Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group: Cardiosphere Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endomyocardial injections of allogeneic Human CSps</intervention_name>
    <description>NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.</description>
    <arm_group_label>Group: Cardiosphere Treatment</arm_group_label>
    <other_name>Biological: Allogeneic Human CSps (or alloCSps)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endomyocardial injections of vehicle only.</intervention_name>
    <description>NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with ischemic cardiomyopathy (EF &gt;10 and &lt;40% by functional imaging [ECHO, CT,
             MRI, contrast ventriculography])

          -  Symptomatic heart failure of NYHA Class 2 or 3

          -  History of prior remote (&gt;3 mo) myocardial infarction and/or documented obstructive
             coronary artery disease with corresponding dysfunctional segments by functional
             imaging

          -  Age &gt; 18 years

          -  Ability to provide informed consent and follow-up with protocol procedures

        Exclusion Criteria:

          -  Documented myocardial infarction within 3 months (120 days)

          -  Known or suspected left ventricular thrombus

          -  Non-cardiovascular disease with life expectancy of &lt; 3 years

          -  Absence of significant gadolinium-enhanced scar (&gt;10% of LV mass) at baseline MRIc

          -  Positive panel-reactive antibodies (PRA)

          -  Need for further revascularization clinically indicated at the time the patient is
             assessed for participation in the clinical trial. This will be determined by a
             cardiologist who is not an investigator in the clinical trial. No further
             revascularization may be indicated by no arteries with significant stenosis, the
             location, and extent of any stenosis may not be suitable for angioplasty, the distal
             vessels may not be suitable for placement of bypass grafts, and/or the patient
             declines angioplasty or bypass surgery.

          -  NYHA IV heart failure

          -  History of aortic stenosis/insufficiency

          -  Requirement for chronic immunosuppressive therapy

          -  Participation in an on-going protocol studying an experimental drug or device

          -  Diagnosis of congenital or genetically-transmitted cardiomyopathy

          -  Current alcohol or drug abuse because of anticipated difficulty in complying with
             protocol-related procedures

          -  Pregnancy or child-bearing potential without use of effective contraception. Men
             intending to &quot;father&quot; children are also excluded.

          -  Human Immunodeficiency virus infection

          -  Viral hepatitis

          -  Uncontrolled diabetes and/or hemoglobin A1C &gt; 8.5%

          -  Abnormal liver function (SGPT &gt; 3 times the upper reference range) and/or hematology
             (hematocrit &lt;25%, WBC &lt;3000, Platelets &lt;100,000) studies without a reversible,
             identifiable cause

          -  Ventricular tachycardia or fibrillation not associated with an acute ischemic episode

          -  Canadian Cardiovascular Society Angina Class 3 or 4

          -  History of cardiac tumor or cardiac tumor demonstrated or suspected on MRI other
             imaging modality

          -  Previous stem cell therapy/treatment

          -  Individuals who are not fluent in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Marban, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center, Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Eduardo Marban, MD, PhD</investigator_full_name>
    <investigator_title>Director, Heart Institute</investigator_title>
  </responsible_party>
  <keyword>Infarction</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Ventricular Dysfunction, Left</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Chronic Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

